GlassScriptPhysician profile
Daniela E Egas Bejar
NPI 1609126846
$245.62
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.54 · 2020: $103 · 2021: $89.72.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $47.21 | 2019-2021 | |
| Csl Behring | $41.35 | 2020-2021 | |
| Neurelis, INC. | $26.59 | 2020 | |
| Amgen INC. | $25.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.00 | 2020 | |
| Livanova USA, INC. | $20.80 | 2020 | |
| Sobi, INC | $17.88 | 2021 | |
| Pierre Fabre Pharmaceuticals, INC. | $17.86 | 2020 | |
| Global Blood Therapeutics, INC. | $13.85 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.76 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Egas Bejar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.